Thursday, January 10, 2019 8:55:14 AM
Jmma, had some time on my hands so thought I would do a chart of Delcath during the subscription period to show what you mentioned for the benefit of the other members on the board.
What is interesting to note is the volumes during the Subscription Period. To me it appears that once they had secured enough subscriptions, they started dumping into the market.
As you so aptly noted, at that point you would have been locked in and could not sell until well after the subscription period ended.
Good Luck to You in 2019!
What is interesting to note is the volumes during the Subscription Period. To me it appears that once they had secured enough subscriptions, they started dumping into the market.
As you so aptly noted, at that point you would have been locked in and could not sell until well after the subscription period ended.
Good Luck to You in 2019!
Anything written herein that you find misspelled, objectionable, incoherent, dim-witted, plagiarized or legally actionable should be attributed to the keyboard Manufacturer, Russian Hackers, Jack Daniels (the drink not the person) or the DNC.
Recent DCTH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
